Foundation One has announced that The Food and Drug Administration (FDA) has approved a “breakthrough device” that has the potential to match cancer patients with more accurate individualized treatment regiments with just one test. This test will push the boundaries of personalized medicine as it might allow us to choose better treatments that are most likely to be effective for specific types of cancer — and to make those decisions sooner.
CHMP Recommends Early Use Of Zytiga
No Bone Metastases - Don't Take Xgeva
Apalutamide - An Oral Androgen Receptor Inhibitor for Non-Metastatic CRPC
A Real-World Analysis Of Outcomes of Early Chemotherapy in Men Newly Diagnosed With Metastatic Prostate Cancer
The FDA Asked To Expand The Label For Zytiga To Allow The Treatment Of Men With Earlier Stages Of Metastatic Prostate Cancer
Xtandi Improves Metastasis Free Survival In Men Who Are Castrate Resistant And Do Not Have Metastasis
Challenge Your Castrate Resistant Prostate Cancer Diagnosis
Some Practical Suggestions When Getting Provenge
Xgeva is Superior To Zometa
Apalutamide - A Potential New Direct Competitor To Xtandi - On The Horizon
Two Studies Released At ASCO Demonstrate A Survival Advantage For Men Who Take Early Zytiga With ADT
Two game changing trials demonstrated that the early use of Zytiga along with hormone therapy (ADT) can provide a significant survival advantage for men with aggressive, hormone naive prostate cancer. The data is very clear for men with metastatic disease, but there remains some controversy if this holds up for men who are not metastatic.
